Related Experiment Video
Updated: Sep 17, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Chronic cavitary pulmonary histoplasmosis treated with isavuconazole after a hypersensitivity reaction to
Miguel E Cervera-Hernandez1, Sunit P Jariwala2
1Infectious Diseases, Sanford University of South Dakota Medical Center, Sioux Falls, 57105, South Dakota, USA.
Abstract:
Chronic cavitary pulmonary histoplasmosis requires prolonged treatment with itraconazole. However, hypersensitivity reactions to itraconazole, though rare, pose a challenge due to limited data on the efficacy and cross-reactivity of the newer azoles. We present a case of chronic cavitary pulmonary histoplasmosis successfully treated with isavuconazole following an itraconazole-induced hypersensitivity reaction, highlighting its potential as an alternative therapy in such cases.
Insights
Chronic cavitary pulmonary histoplasmosis treatment can be challenging due to itraconazole hypersensitivity. Isavuconazole offers a promising alternative therapy for patients experiencing adverse reactions to itraconazole.
Area of Science:
- Mycology
- Pulmonology
- Infectious Diseases
Background:
- Chronic cavitary pulmonary histoplasmosis (CCPH) necessitates long-term antifungal treatment, typically with itraconazole.
- Hypersensitivity reactions to itraconazole, while uncommon, present a significant clinical challenge in managing CCPH.
- Limited data exists on the efficacy and cross-reactivity of newer azole antifungals in CCPH patients with itraconazole intolerance.
Observation:
- A patient with CCPH developed a hypersensitivity reaction to itraconazole, precluding its continued use.
- Alternative azole antifungal therapy was considered due to the need for sustained treatment of CCPH.
Findings:
- The patient was successfully treated with isavuconazole after experiencing an itraconazole-induced hypersensitivity reaction.
- This case demonstrates the successful use of isavuconazole in a patient with CCPH who could not tolerate itraconazole.
Implications:
- Isavuconazole represents a viable and effective alternative treatment option for CCPH in patients with itraconazole hypersensitivity.
- Further research into the role of newer azoles like isavuconazole in managing complex fungal infections is warranted.
- This case contributes to the understanding of azole cross-reactivity and treatment strategies for refractory or intolerant histoplasmosis cases.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Allergic Drug Reactions
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

